Medicines made to measure

Bioalps networking day 2010Programme

Personalised medicine

BioAlps is supported by the Cantons of Berne, Fribourg, Vaud, Neuchâtel, Geneva, Valais and Jura, by the Swiss State Secretariat for Economic Affairs (SECO), and by all key research institutions in the region.

29 Sept. 2010 / 09:00 – 14:00 at merck Serono9, Chemin des mines, geneva

All the right reasons to be here!our annual networking event aims to bring people together around a shared interest in life sciences, irrespective of whether they are professionals or students, with industrial, academic, economic or political backgrounds, from switzerland, France or further abroad. last year’s theme was infectious diseases, focusing notably on aids, malaria, tuberculosis and certain neglected diseases. some 30 speakers, including representatives from foundations, non-governmental organisations, academia and industry, and 300 participants attended the event, which took place in the Merck serono headquarters in geneva. please feel free either to pick up or to order a retrospective guide of last year’s event, if you do not already have one, in which you will find the wide variety of experts in infectious diseases in the region.

3

“It is a pleasure for Merck Serono to see how the BioAlps Networking Day has grown in importance over the past five years to become a landmark event in our calendars, and we are looking forward to a continued partnership with BioAlps for the benefit of the life science community.”tomas roztocil, external relations Manager

the health care sector is experiencing a medical revolution. preventive, predictive and personalised medicine is taking more and more space. this is the reason why, following on from bioconvergence i.e. the study of the interfaces between biotech and medtech which was our main focus over the past year, we decided to explore personalised medicine, notably its key drivers and barriers. personalised medicine will also be the theme of our 2010 special annual review magazine, to be published in the autumn in partnership with Bilan. the publication is an excellent opportunity to read and learn more about the subject… personalised medicine is currently very topical; this is because all the conditions for it to emerge seem to be present. it remains to be seen what all the ingredients of this apparently fertile area are, and how or why it is important to be part of the drive towards personalised medicine…

On behalf of the BioAlps Committee,Benoît Dubuis, President, and Ariane Vlérick, Secretary General

2010

4

Valérie Junod (UNIGE/UNIL, Professor)

Discussion moderated by Fabrice Delaye, journalist at Bilan magazine

10:25 – 10:55 Coffee break

10:55 – 11:40 Companies developing personalised medicines(5 mn per speaker)

rudi pauwels (Biocartis, CEO)

Jonathan knowles (Caris Life Sciences, CSO)

stavros therianos (Diagnoplex, CEO)

didier Mauroy (Biofield, CEO)

Frédéric reymond (DiagnoSwiss, General Manager)

olivier Chételat (Centre Suisse d’Electronique et deMicrotechnique, Section Head Control and Signal Processing Systems)

Frédéric eberlé (Roche Diagnostics France, Head Medical Division Lab Network) 11:40 – 12:30 Perspectives & tendencies in personalised medicine

elmar schnee (Merck KGaA, Member of the Executive Board and General Partner; Merck Serono, President)

Jean-paul rigaudeau (Unilabs, CEO)

eric Manck (Biomérieux, CEO Swiss subsidiary)

Discussion moderated by Benoît Dubuis

7

8:30 – 9:00 arrival 9:00 – 9:10 Welcome

tomas roztocil (Merck Serono, External Relations Manager)

Benoît dubuis (BioAlps, President) 9:10 – 9:50 What the research in our region teaches us(10 mn per speaker)

dany Mercan (Unilabs, Scientific Head Special Chemistry)

ioannis Xenarios (Swiss Institute of Bioinformatics, Director of the Vital-IT Centre and of the SwissProt group)

ilhan Celik (Merck Serono, Head of Biomarker Strategy Oncology)

denis Hochstrasser (HUG/UNIGE, Vice-Dean of the Faculty of Medicine, Chairman of the Department of Genetics and Laboratory Medicine)

9:50 – 10:25 Personalised medicine & society

pietro scalfaro (Debiopharm, Director, Business Unit Diagnostics)

Jean-yves le Cotonnec (Triskel, CEO)

Programme

6

12:30 – 13:00 Bioalps award

speech by Jean-dominique Vassalli (UNIGE, Rector)

Bioalps award and presentation of the two recipients by Benoît dubuis (BioAlps, President) and ariane Vlérick (BioAlps, Secretary General)

Brief laudatory by Frédéric neftel (Debiotech S.A., President & CEO)

Brief laudatory by paul stoffels (Johnson & Johnson, Company Group Chairman, Global Research & Development, Pharmaceuticals)

speech by andrea rappagliosi (EuropaBio, Chair of the Board) 13:00 – 14:00 Networking Cocktail

The graphic artist Ralph Kaiser will be illustrating the main themes of the event.

8

Many players are already working in our region to achieve the promising perspectives that are being opened up by the development of personalised medicine. we look forward to helping you discover them; they are here for you today!

Our Speakers

11

Holder of a phd degree in robotics from the ecole polytechnique Fédérale de lausanne (epFl) in switzerland since 1997, olivier Chételat spent one year as a post-doctoral fellow at Johns Hopkins (Usa) in 1998 and two years in 2000 and 2001 as assistant professor at Busan national University (south korea). He joined the Centre suisse d’electronique et de Microtechnique (CseM) in 2001, where he has since been involved in the management of several projects, in particular projects for the european space agency (esa) related to vital parameter monitoring. He has also played an active role as technical expert in several research programmes, including european projects and commercial projects focused on eCg, impedance, spo2 and core body temperature sensors. since 2009, he has been section Head of Control and signal processing at CseM.

Olivier CHETELAT

13

Head of Biomarker strategy oncology at Merck serono, ilhan Celik (prof. dr. med.) graduated in medicine from the University of Marburg (germany) and holds a Full professorship of experimental Medicine and preclinical/clinical oncological research. He joined Merck serono in 2006. in 2008, he moved to the global Clinical development Unit oncology as Manager of Clinical Biomarker development oncology, responsible for worldwide clinical biomarker development. in July 2010, he became Manager of Biomarker strategy oncology in the global Clinical development Unit oncology at Merck serono in darmstadt (germany) in charge of all aspects of the company’s Biomarker strategy in oncology.

Ilhan CELIK

12

with more than 15 years of international experience in the life sciences, Benoît dubuis (Chem ing epFl, phd etH, Mte iMd) has worked both in industry and in academic science management. He occupied different management positions in pharmaceutical companies, including Chemap, Ciba-geigy/novartis and lonza. in 2000, he joined the ecole polytechnique Fédérale de lausanne (epFl) as licensing executive and adviser for the school management. He established the school of life sciences and served as its first dean. Benoît dubuis is a founder of excellgene s.a. and Bioalps, as well as of the first swiss life sciences seed fund and incubator, eclosion. in addition to his appointments at eclosion and at the epFl, he is a respected adviser for various leading pharmaceutical and biotech companies and serves on several Boards and advisory Boards. He has been the president of Bioalps since 2008. He has also published numerous articles and books in the field of biotechnology and science communication.

Benoît DUBUIS

15

aged 45, Fabrice delaye started journalism in 1991 after graduating from the institut d’etudes politiques de paris. after free-lancing for various swiss and French newspapers such as l’agefi, le Figaro and le Monde, he joined the staff of swiss magazine l’Hebdo in 1994 and started focusing on economy, technology and science. From 1996 to 1999, he served as staff technology reporter for the magazine Bilan in switzerland. in 1999, he went back to university and graduated with a Master in society, science and technology from the ecole polytechnique Fédérale de lausanne (epFl). He then joined the daily swiss economic newspaper l’agefi, where he served first as a Us correspondent in Boston, then as european correspondent in paris. since september 2006, Fabrice delaye has been the international correspondent of swiss magazine Bilan, based in paris. He also writes regularly for science Business, a web-based publication.

Fabrice DELAYE

14

Chairman of the genetic & laboratory Medicine department of the University Hospitals of geneva (HUg) and Vice dean of the Faculty of Medicine in geneva, dr. denis Hochstrasser is also Head of the laboratory Medicine division of the HUg, switzerland’s largest acute hospital. He still practises as a Board-certified physician. at the academic level, he is full professor both to the University of geneva’s department of structure Biology & Bioinformatics, Faculty of Medicine, and to the school of pharmacy, Faculty of sciences. He was one of the founders of the swiss institute for Bioinformatics (siB), of the swiss Centre for applied Human toxicology and also of the Biobank swiss Foundation. He is a scientific founder of geneva proteomics inc, geneva Bioinformatics s.a. and of eclosion s.a. His research focuses on the discovery of clinical biomarkers in diseases of the brain, pancreas and kidney, in human toxicology and the development of proteomic and clinical chemistry-related technologies.

Denis HOCHSTRASSER

17

specialised in molecular biology, Frédéric eberlé first studied medicine and clinical biology. in 1995, he joined the French affiliate of the roche diagnostics division to launch viral load assays and qualitative rna HCV and HiV tests in blood transfusion. He now acts as Medical Manager in the Business development division, in charge of collaboration with French clinical and biological experts to evaluate the medical added value of new assays developed by the roche group. He is in close contact with his pharma (paris) colleagues for companion tests of new roche pharma drugs.

Frédéric EBERLE

16

the unifying thread of ralph kaiser’s work is the art of drawing, as a tool for research, visualisation and popularisation. ralph kaiser completed his education as a graphic designer in 1988 and went on to work for five years with museographer serge tcherdyne. in 1994, he founded jkdesign with industrial designer stéphane Jacquenoud, and for 10 years conducted projects in museography and design. in 2004, he founded studio ko. since that time, Mr. kaiser has continued to develop his research as a creator: scenography, design, spatial layout, signposting, cartoons and illustrations.

Ralph KAISER

19

specialised in pharmaceutical law, Valérie Junod is a law professor at HeC lausanne University and at the geneva law school. she has an llM from University of pennsylvania and a JsM from stanford University. she has a particular focus on clinical trials, advertising regulations and reimbursement issues. she sits on the University Hospitals of geneva (HUg) ethics committee. Valérie Junod also practises as a lawyer at a geneva law firm.

Valérie JUNOD

18

Ceo since 1995 of triskel integrated services s.a., a company which provides strategic services to the pharmaceutical industries, Jean-yves le Cotonnec holds an Md diploma, for which he wrote a thesis in obstetrics, an advanced degree in engineering, for which he wrote a thesis in data processing, and an Msc in Mathematics and statistics. after gaining his early experience in clinical development in the novartis group, dr. le Cotonnec served as Corporate Vice president, safety and Medical sciences for the ares-serono group of geneva, switzerland, where he directed the worldwide preclinical and clinical development of six recombinant drugs and several peptides and biologics. at triskel integrated services s.a., he was instrumental in the development or registration of approximately 60 drugs for eU and Us clients. Most of these products are now successfully marketed worldwide.

Jean-Yves LE COTONNEC

21

Head of group research and Member of the executive Committee at roche until 2009, pr. Jonathan knowles is a global opinion leader in personalised medicine. He was the Chairman of the Corporate governance Committee and a Member of the Board at genentech for the last 12 years, as well as a member of the Chugai pharmaceuticals Board for seven years. Jonathan knowles was recently appointed professor of translational Medicine at the ecole polytechnique Fédérale de lausanne (epFl) in switzerland, holds a distinguished professorship in personalised Health Care at the Finnish institute for Molecular Medicine (FiMM) at the University of Helsinki, and has been appointed to a Visiting Chair at the University of oxford. at the beginning of 2010, pr. knowles joined the Board of Caris life sciences, an international cutting-edge molecular diagnostics company based in irving, texas. since May 2010 pr. knowles has also assumed the role of Caris’ Chief scientific officer.

Jonathan K.C. KNOWLES

20

a Belgian native, dr. didier Mauroy is the Ceo of Biofield s.a. He studied at liege University where he received a doctorate in Veterinary Medicine and a Master in Hygiene and Food technology. later, he received a Master in Business from the solvay Brussels school of economics and Management. dr. Mauroy started his professional life as a veterinary surgeon. He has fifteen years’ international experience in breeding and foodstuffs. since the 1990s, dr. Mauroy has worked on publications that give indications for predictive biological risk. in 1999, he joined an incubator to develop an autonomous buoy for the real time prediction of water microbiological risk. the same year, he received the anvar award. dr. Mauroy then decided to use this experience to turn towards micro-electro-mechanical systems (MeMs) for predictive diagnosis. He funded U-Cell in Bordeaux in 2006 and Biofield s.a. in neuchatel in 2008 for the development of an easy-use lab-on-a-chip for predictive medicine.

Didier MAUROY

23

general Manager of BioMérieux (suisse) s.a. since 2008, eric Manck graduated from the University of tours, in France, in Cellular Biology. after several sales trainings, and four years as sales engineer at iBM France, eric Manck joined BioMérieux as sales representative in 1992. He occupied kaM apHp marketing responsibilities before becoming Marketing Manager for immunoassays, and was promoted to regional Business Manager in 2007.

Eric MANCK

22

with a medical degree from paris-necker University Hospital, Frédéric neftel started his career with debiopharm s.a. on the clinical development of somatostatin analogues, in collaboration with nobel prize laureate andrew schally, and on the development and licensing of novel pharmaceutical drug compounds. in 1990, he founded debiotech s.a. in lausanne, switzerland, where he is currently acting as president and Ceo. debiotech specialises in the research and development of innovative medical devices and drug delivery systems. over the past 20 years debiotech has concluded more than 50 licensing deals with leading companies in the pharmaceutical and device fields and holds over 500 patents worldwide. the company is particularly active in micro- and nanotechnologies for implantable and external drug delivery systems, used in areas such as diabetes therapy, renal failure, cardiovascular stents, cancer and pain treatments, vaccines and diagnostics. in 2004, Frédéric neftel founded “swiss Medical Care s.a.”, a spin-off company of debiotech, which is developing and marketing novel contrast media injector systems for Ct imaging and diagnostics.

Frédéric NEFTEL

25

in charge of special Chemistry testing and the Biocheckup project, dany Mercan is the scientific Manager at Unilabs’ clinical laboratories in Coppet. Born in Brussels, Belgium, dr. Mercan studied Medicine at Free University of Brussels then further specialised in laboratory Medicine and obtained a thesis in Medical sciences. He has fifteen years of experience in developing specialised tests by various complex techniques involving mainly chromatography, atomic absorption and mass spectrometry, first in the academic sector and thereafter for private hospitals and laboratories. His specialised expertise includes preanalytical stabilisation of samples, human nutrition and lifestyle diseases. He joined Unilabs in 2004.

Dany MERCAN

24

Currently Chair of the Board of europaBio, the european association of Bioindustries, andrea rappagliosi is Vice president european government affairs and Head of the Brussels office for glaxosmithkline. a lawyer by education, andrea rappagliosi began his career in the early 1980s, first in the italian government and then in the italian senate. in 1992, Mr. rappagliosi moved to the private sector and gained more than fifteen years of experience in public affairs, health policy and market access at companies including serono, Baxter and Merck serono. andrea rappagliosi is a founding member of the international society of Health technology assessment (Htai).

Andrea RAPPAGLIOSI

27

author and co-author of more than 150 publications in peer reviewed journals, rudi pauwels is a scientist-entrepreneur who completed his phd in pharmaceutical sciences at the rega institute for Medical research (University of leuven) in Belgium in 1990. He has received several awards for his scientific and entrepreneurial initiatives and serves on the Board of several companies and research institutes. rudi pauwels founded and built up three successful biotechnology companies: tibotec, Virco and galapagos genomics. Both his research and his entrepreneurial career are driven by medical needs for which he tries to find innovative solutions. He is a strong believer in the value of a multi-disciplinary scientific, technological and clinical approach to solve key pharmaceutical and diagnostic challenges. He executes his plans with the help of carefully selected people who are also motivated ‘to make a difference’. Following a three-year sabbatical at the ecole polytechnique Fédérale de lausanne (epFl) in switzerland, where he became more familiar with the advances in micro- and nanotechnologies, dr. pauwels created Biocartis to address new needs in the field of diagnostics.

Rudi PAUWELS

26

general Manager of diagnoswiss, a private company specialised in electrochemical microchips for protein analysis, Frédéric reymond is a chemical engineer from the ecole polytechnique Fédérale de lausanne (epFl), where he obtained his phd in electrochemistry in 1997. after two years as a post-doctoral fellow at lepa-epFl, dr. reymond co-founded diagnoswiss in 1999, where he gained experience in the international bioanalysis and diagnostic industries, with specific expertise in contract negotiations and licensing, ip protection, r&d project management, corporate administration and finances. dr. reymond now shares his time between diagnoswiss and Mondema, where he acts as Manager of the operation, Quality & Maintenance department. dr. reymond is 41 years old, and he is co-author of more than 50 scientific papers and 17 patents.

Frédéric REYMOND

29

appointed full professor at the ecole polytechnique Fédérale de lausanne (epFl) in 1997, where he had been since 1993, philippe renaud’s current research interests are in microfluidics, cell chips, nanofluidics and biomedical devices. He is also director of the epFl Centre of Micronanotechnology (CMi), a large clean-room facility with processing equipment for training and scientific experimentation in microelectronic and micro-fabrication processes. since 1996, he has been founding member and organiser of the international nanobiotech Conference in Montreux. prior to joining the epFl, pr. philippe renaud worked in the sensors and actuators group at the swiss Centre for electronics and Microtechnology (CseM) in neuchâtel, switzerland. He completed his diploma in theoretical physics from the University of neuchâtel and his phd in experimental physics from the University of lausanne, switzerland. He conducted his postdoctoral research first at the University of California, Berkeley, Usa, and then at the iBM Zurich research laboratory in switzerland. philippe renaud is co-founder of Biocartis, a company specialised in molecular diagnostics, as well as scientific adviser for several other companies.

Philippe RENAUD

28

Manager external relations at Merck serono, tomas roztocil graduated in biochemistry from the University of geneva and holds a phd in the field of neuroscience. He pursued a career in research in developmental biology at the University of California san Francisco and joined Merck serono in 2000 as a clinical research scientist. in 2001, he moved towards communications, as Manager of scientific and Medical Communications, responsible for worldwide strategy in Fertility, endocrinology and later oncology. He has been in his current position since 2007, in charge of relationships with industry, academia and local communities. tomas roztocil also manages Merck serono’s Corporate social responsibility activities.

Tomas ROZTOCIL

31

since May 2009 Ceo of Unilabs, europe’s leading diagnostic services company with a presence in 12 countries, Jean-paul rigaudeau is a French citizen and holds a Masters degree in Business administration from Columbia University (Usa). He started his career in the consumer goods industry with Beiersdorf (nivea), where he served in various positions in marketing and general management in a number of countries (Usa, germany, Japan, spain, Mexico, latin america). He then joined Johnson&Johnson as Managing director for germany and austria. He moved to kraft Foods in 2004 as Managing director for germany, before taking over responsibility for the areas of germany, austria and switzerland. Mr. rigaudeau was promoted to Vp europe Chocolate in 2007 and to president europe region in January 2008.

Jean-Paul RIGAUDEAU

30

elmar schnee is a Member of the executive Board and general partner of Merck kgaa, and the president of Merck serono. a native of switzerland, Mr. schnee studied at the Zurich-based swiss institute for Business administration where he received a degree in Marketing Management. He has more than twenty years’ experience in the international pharmaceutical industry, with specific expertise in business development and marketing gained at companies including Fisons pharmaceutical, sanofi-synthélabo and UCB pharma. Mr. schnee joined Merck in May 2003 as Managing director of the Merck santé s.a.s. subsidiary in lyon, France. in 2006, he was appointed regular Member of the executive Board and general partner of Merck kgaa, with responsibility for pharmaceuticals.

Elmar SCHNEE

33

Head of debiopharm group’s Business Unit for diagnostics and personalised Medicine since 2008, pietro scalfaro joined debiopharm in 2002, led drug development programmes and created the project department. He was instrumental in advancing debio’s first-in-class anti-HCV drug from preclinical to proof of concept, debio 025 licensed to novartis. as Md certified in pediatric intensive Care Medicine, he practised for 13 years in switzerland, australia and France. through his clinical and research experience with life-threatening diseases, artificial ventilation, monitoring devices and infectious diseases, he understood the value of a multi-disciplinary approach to obtain valid solutions at the therapeutic and diagnostic interface. since 2010, he has been serving as director on the Board of Biocartis, a start-up engaged in the development of diagnostics platforms for multiplexed detection of molecular-based biomarkers.

Pietro SCALFARO

32

Founder and Ceo of diagnoplex s.a., stavros therianos has a basic training as a molecular biologist from the University of Basel and as a psychologist from the University of lausanne. dr. therianos was assistant professor at the University of rochester Medical Center, new york, Usa, before he started diagnoplex in 2004.

Stavros THERIANOS

35

Belgian Md paul stoffels studied Medicine at the University of Hasselt and the University of antwerp, and infectious diseases and tropical Medicine at the prince leopold institute of tropical Medicine in antwerp, Belgium. stoffels worked for four years as a physician and researcher of HiV/aids in africa. in 1991, he returned to Belgium and became the Head of development for HiV compounds at Janssen pharmaceutica in Beerse, Belgium. in 1993, he was promoted to director of Clinical research and development for infectious diseases and dermatology. in 1997, he left Janssen pharmaceutica and together with rudi pauwels co-founded the biotech companies tibotec and Virco. when Johnson & Johnson acquired tibotec-Virco in april 2002, he became Company group Chairman of the global Virology Franchise at Johnson & Johnson and Chairman of tibotec.

Paul STOFFELS

34

Bioengineer and holder of a phd in life sciences from the Free University of Brussels, ariane Vlérick has always brought her interests in literature, art and sports to bear in her professional scientific life (see her site www.defisciences.info). she was instrumental in setting up programmes, on behalf of the Free University of Brussels, to encourage citizens, and in particular young people, to become interested in science, then moved on to take over full editorial responsibility for the scientific, technical and medical sectors of international scientific French-speaking publisher de Boeck. in 2005, she moved to switzerland, and managed communications, major events on the subject of science for various audiences and media relations for several scientific institutions such as the Faculty of Medicine of the University of geneva, the school of life sciences of the ecole polytechnique Fédérale de lausanne, the Brocher Foundation, and the world knowledge dialogue Foundation. she became secretary general of Bioalps in 2009.

Ariane VLERICK

37

rector of the University of geneva, Jean-dominique Vassalli obtained his swiss Federal diploma of medicine at the University of geneva in 1972, his phd in sciences at rockefeller University in 1977 and his doctorate in medicine at the University of geneva in 1984. ten years later he was appointed Vice dean of the Faculty of Medicine. in 1999, he was appointed Vice rector of the University of geneva, a position he held until 2003. He was notably responsible for the collaboration between Vaud and geneva and the valorisation of scientific discoveries. From 2004 to July 2007, he presided the Fundamental Medicine section of the Faculty of Medicine. in July 2007, he was appointed rector of the University of geneva.

Jean-Dominique VASSALLI

36

director of swiss-prot and Vital-it, ioannis Xenarios received a phd in immunology from the ludwig institute of Cancer research and the institute of Biochemistry in lausanne. He worked on the development of the database of interacting proteins (dip) under the supervision of pr. david eisenberg at the University of California los angeles in the Usa. He then became Head of translational Bioinformatics at serono (now Merck serono), where his group developed computational methodologies in the areas of proteomics, microarray and genetics. He is one of the principal investigators of the enFin project, which aims to provide methods in dynamic systems modeling.

Ioannis XENARIOS

38

western switzerland is a vibrant region for the life science industry. the purpose of the Bioalps award, which is now traditionally awarded at the occasion of the Bioalps networking day, is to honour and thank a person from a life science background without whom western switzerland would not have its renowned international reputation in this sector. last year, Mr. Benoît dubuis (president of the Bioalps association) and Mr. pierre-François Unger (state Councillor in charge of the department of regional affairs, economy and Health, republic and state of geneva) had the great pleasure of awarding this to rolland-yves and thierry Mauvernay for their daily commitment to furthering development of the life sciences in the region. the Mauvernay family founded debiopharm, a global biopharmaceutical group based in western switzerland, which focuses on the development of prescription medication for unmet medical needs.

The BioAlps Award

40

the trophy awarded to the winners of the Bioalps award symbolises the main strength of our institutions: an interdisciplinarity which plays a crucial role in the development of the life sciences. the study of life sciences is now more than ever at the interface between a whole range of disciplines spanning chemistry, biology and micro- and nanotechnologies to it and material sciences. this trophy – made of glass to symbolise research – includes the dna helix, the chemist’s serpent and a cog which represents both the technologies supporting development of the life sciences and the complexities of the mechanisms of life.

trophy

42

you will have the pleasure of discovering who this year’s Bioalps award winners will be at the end of our session – just before sharing a friendly networking cocktail event. after a speech by pr. Jean-dominique Vassalli, rector of the University of geneva, the award will be given to the laureates by Benoît dubuis and ariane Vlérick, who will outline their achievements in and contributions to the life sciences. paul stoffels and Frédéric neftel will say a few words on the reasons why the winners are both great people and well-respected personal friends. Finally, the closing words will be said by andrea rappagliosi, who joins us not only as the Chair of the Board of europaBio, but also as a past member of the Bioalps network and previous executive of Merck serono. Join us in applauding both laureates and speakers! enjoy the event!

44

who will be this year’s winners?

4746

4948

50

Project management www.bioalps.org

editingwww.genevensis.com

Designwww.oxyde.ch

Photo lithographywww.atelierzed.ch

PrinterFavre & Winteregg

Photography www.cedricbregnard.ch Loris Von SiebenthalBBP / EPFL www.istockphoto.com www.shutterstock.com

Address BioAlps Association c/o OPI Rte des Jeunes 9 Case postale 1011 1211 Geneva 26 Switzerland

Contact Dr Ariane Vlérick Secretary General Phone +41 (0) 22 304 4040 E-mail ariane.vlerick@bioalps.orgWeb www.bioalps.org